10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“practice guidelines increasingly recognize the prevention of ischemic events as a key management priority.5,6”
In the citing paper
“However, subsequent trials that specifically examined the role of a blood pressure lowering strategy to <130 mm Hg in patients with T2DM and hypertension found no substantive benefit of intensive blood pressure control in reducing the risk of coronary events, although there was evidence for decreased risk of stroke.5,66–69”
In the citing paper
“As such, while all patients with T2DM and CAD certainly benefit from a blood pressure of <140/90 mm Hg,5,63–66,76”
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
In the citing paper
“Furthermore, fibrates or fish oil would be indicated when triglycerides are very high (>500 mg/dL) to reduce the risk of pancreatitis.5”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Research works printed but not linked: 2
- American College of Obstetricians and Gynecologists’, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Fitchett, 2017, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial, Eur Heart J, 39, 363, 10.1093/eurheartj/ehx511 · DOI · Paper page
Cited by
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
ACC/AHA Versus ESC/ESH on Hypertension Guidelines
Bakris, G., Ali, W., & Parati, G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.507 · Cited by 319
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Hypertension in pregnancy: Pathophysiology and treatment
Braunthal, S., & Brateanu, A. (2019) · SAGE Open Medicine · doi:10.1177/2050312119843700 · Cited by 263
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Kim, M. K., Ko, S.-H., Kim, B.-Y., Kang, E. S., Noh, J., Kim, S.-K., Park, S.-O., Hur, K. Y., Chon, S., Moon, M. K., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0137 · Cited by 216
An Effective Model of Diabetes Care and Education: Revising the AADE7 Self-Care Behaviors ®
American Association of Diabetes Educators (2020) · The Diabetes Educator · doi:10.1177/0145721719894903 · Cited by 184
Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis
Li, X., Weber, N. C., Cohn, D. M., Hollmann, M. W., DeVries, J. H., Hermanides, J., & Preckel, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112419 · Cited by 181
Fu, L., Zhou, Y., Sun, J., Zhu, Z., Xing, Z., Zhou, S., Wang, Y., & Tai, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01393-5 · Cited by 164
Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0871-8 · Cited by 159
Role of aspirin in primary prevention of cardiovascular disease
Patrono, C., & Baigent, C. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0225-y · Cited by 172
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136
Arnold, S. V., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Mues, K. E., Alam, S., Elliott-Davey, M., Bhatt, D. L., Cannon, C. P., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041730 · Cited by 130
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Lipoprotein (a) and diabetes mellitus
Lamina, C., & Ward, N. C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.016 · Cited by 120
ACC/AHA lipid guidelines: Personalized care to prevent cardiovascular disease
Reiter–Brennan, C., Osei, A. D., Uddin, S. M. I., Orimoloye, O. A., Obisesan, O. H., Mirbolouk, M., Blaha, M. J., & Dzaye, O. D. A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19078 · Cited by 114
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety
Bai, Y., Zhu, R., Tian, Y., Li, R., Chen, B., Zhang, H., Xia, B., Zhao, D., Mo, F., Zhang, D., et al. (2019) · Molecules · doi:10.3390/molecules24183302 · Cited by 91
Grabež, M., Škrbić, R., Stojiljković, M. P., Rudić-Grujić, V., Paunović, M., Arsić, A., Petrović, S., Vučić, V., Mirjanić-Azarić, B., Šavikin, K., et al. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103692 · Cited by 85
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Verma, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.028 · Cited by 83
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Stote, K. S., Wilson, M. M., Hallenbeck, D., Thomas, K., Rourke, J. M., Sweeney, M. I., Gottschall‐Pass, K. T., & Gosmanov, A. R. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa030 · Cited by 92
Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Hypertension and diabetes mellitus: highlights of a complex relationship
Yildiz, M., Esenboğa, K., & Oktay, A. A. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000748 · Cited by 93
Løgstrup, B. B., Ellingsen, T., Pedersen, A. B., Darvalics, B., Olesen, K. K. W., Bøtker, H. E., & Mæng, M. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa374 · Cited by 78
Engström, M. S., Leksell, J. K., Johansson, U., Borg, S., Palaszewski, B., Franzén, S., Guðbjörnsdóttir, S., & Eeg‐Olofsson, K. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1212-z · Cited by 82
Li, M., Xu, Y., Wan, Q., Shen, F., Xu, M., Zhao, Z., Lu, J., Gao, Z., Chen, G., Wang, T., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0256 · Cited by 68
Nanna, M. G., Kolkailah, A. A., Page, C., Peterson, E. D., & Navar, A. M. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3839 · Cited by 66
Ferrari, F., Bock, P. M., Motta, M. T., & Helal, L. C. A. S. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190224 · Cited by 107
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events
Yang, Y., Peng, N., Chen, G., Wan, Q., Li, Y., Wang, G., Qin, Y., Luo, Z., Tang, X., Huo, Y., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01447-2 · Cited by 82
Diabetes Diagnosis and Control: Missed Opportunities to Improve Health
Cowie, C. C. (2019) · Diabetes Care · doi:10.2337/dci18-0047 · Cited by 68
Zhou, K., Qin, Z. H., Tian, J., Cui, K., Yan, Y., & Lyu, S. (2021) · Angiology · doi:10.1177/00033197211012129 · Cited by 65
Katsiki, N., Banach, M., & Mikhailidis, D. P. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.89449 · Cited by 69
Pané, A., Conget, I., Boswell, L., Ruiz, S., Viñals, C., Perea, V., Giménez, M., Cofán, M., Blanco, J., Vinagre, I., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3323 · Cited by 65
McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14162 · Cited by 58
Fan, W., Philip, S., Granowitz, C. B., Toth, P. P., & Wong, N. D. (2019) · Diabetes Care · doi:10.2337/dc19-0501 · Cited by 62
Hu, Y., Bai, Z., Tang, Y., Liu, R., Zhao, B., Gong, J., & Mei, D. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3695101 · Cited by 56
Awareness, treatment, control, and determinants of dyslipidemia among adults in China
Opoku, S., Gan, Y., Addo‐Yobo, E. O. D., Tenkorang-Twum, D., Yue, W., Wang, Z., & Lu, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-89401-2 · Cited by 67
Blood pressure targets in adults with hypertension
Arguedas, J. A., Leiva, V., & Wright, J. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004349.pub3 · Cited by 55
Sphingolipid metabolism in type 2 diabetes and associated cardiovascular complications
Sui, J., He, M., Wang, Y., Zhao, X., He, Y., & Shi, B. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7981 · Cited by 66
“CVD is the leading cause of morbidity and mortality for individuals with diabetes and results in 30% of all deaths, with this figure expected to increase in the next 10 years (2,3).”
Shao, S., Chang, K., Lin, S.-J., Chien, R., Hung, M., Chan, Y., Yang, Y. K., & Lai, E. C. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0990-2 · Cited by 62
Shah, V. N., Bailey, R. J., Wu, M., Foster, N. C., Pop‐Busui, R., Katz, M. L., Crandall, J. P., Bacha, F. F., Nadeau, K. J., Libman, I. M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa015 · Cited by 60
Dulaglutide: A Review in Type 2 Diabetes
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01260-9 · Cited by 56
Ribeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 56
Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study
Wu, H., Lau, E. S. H., Yang, A., Ronald, C. W., Kong, A. P. S., Chow, E., So, W., Chan, J. C. N., & Luk, A. O. Y. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01039-y · Cited by 55
Nelson, A. J., Ardissino, M., Haynes, K., Shambhu, S., Eapen, Z. J., McGuire, D. K., Carnicelli, A., Lopes, R. D., Green, J. B., O’Brien, E. C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.016835 · Cited by 50
“Notwithstanding this, the most recent updates of the American and European guidelines consistently recommend these therapies, 16–19 and thus this analysis, in some respects, represents a starting landscape of clinical care.”
Yonekawa, Y., Modi, Y. S., Kim, L. A., Skondra, D., Kim, J. E., & Wykoff, C. C. (2020) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419893829 · Cited by 55
Barbhaiya, M., Feldman, C. H., Chen, S. K., Guan, H., Fischer, M. A., Everett, B. M., & Costenbader, K. H. (2020) · Arthritis Care & Research · doi:10.1002/acr.24328 · Cited by 49
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
Dabravolski, S. A., Zhuravlev, A. D., Kartuesov, A. G., Borisov, E. E., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105371 · Cited by 56
Muscle Insulin Resistance and the Inflamed Microvasculature: Fire from Within
Liu, J., & Liu, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030562 · Cited by 50
The Cardiometabolic Risk Profile of Young Adults With Diabetes in the U.S.
Saydah, S. H., Siegel, K. R., Imperatore, G., Mercado, C., & Gregg, E. W. (2019) · Diabetes Care · doi:10.2337/dc19-0707 · Cited by 44
Detection of Cardiac arrhythmia using fuzzy logic
Kora, P., Meenakshi, K., Swaraja, K., Rajani, A., & Islam, M. K. (2019) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2019.100257 · Cited by 51
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective
Rocca, B., & Patrono, C. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108008 · Cited by 48
Thomas, M., Magwire, M., Gosch, K., Sammour, Y., Mehta, R., O’Keefe, J., Nassif, M. E., & Kosiborod, M. (2021) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007682 · Cited by 46
Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease
Marquis‐Gravel, G., Roe, M. T., Harrington, R. A., Muñoz, D., Hernandez, A. F., & Jones, W. S. (2019) · Circulation · doi:10.1161/circulationaha.119.040205 · Cited by 51
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 50
Tai, S., Fu, L., Zhang, N., Zhou, Y., Xing, Z., & Wang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.858209 · Cited by 51
Alfian, S. D., van Boven, J. F. M., Abdulah, R., Sukandar, H., Denig, P., & Hak, E. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14610 · Cited by 53
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Song, F., Mao, Y.-J., Hu, Y., Zhao, S., Wang, R., Wu, W., Li, G., Wang, Y., & Li, G. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174916 · Cited by 44
Ray, K. K., Del Prato, S., Müller-Wieland, D., Cariou, B., Colhoun, H. M., Tinahones, F. J., Domenger, C., Letierce, A., Mandel, J., Samuel, R., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0951-9 · Cited by 43
“In the 2018 US cholesterol guidelines from the American College of Cardiology, American Heart Association, 2019 ESC/EAS guidelines, and others, individuals with clinical ASCVD are categorized as being at very high risk for cardiovascular (CV) events if they have additional risk factors, including diabetes and elevated…”
BackgroundProtective effects of catalpol on cardio-cerebrovascular diseases: A comprehensive review
Zhang, Z., Dai, Y., Xiao, Y., & Liu, Q. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.06.010 · Cited by 48
Paiman, E. H. M., van Eyk, H. J., van Aalst, M. M. A., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed‐Duijvestijn, P. H., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2020) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 41
Zhang, H., Zhang, Q., Luo, D., Cai, X., Li, R., Zhang, Y., Lu, Y., Liu, J., Gu, J., & Li, M. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16082 · Cited by 41
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Kim, M. K., Han, K., Joung, H. N., Baek, K., Song, K., & Kwon, H. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0943-9 · Cited by 49
Parker, W. A., Schulte, C., Barwari, T., Phoenix, F. A., Pearson, S. M., Mayr, M., Grant, P. J., Storey, R. F., & Ajjan, R. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0981-3 · Cited by 43
Morieri, M. L., Shah, H., Sjaarda, J., Lenzini, P. A., Campbell, H., Motsinger‐Reif, A. A., Gao, H., Lovato, L., Prudente, S., Pandolfi, A., et al. (2020) · Diabetes · doi:10.2337/db19-0973 · Cited by 46
Chu, H., Chen, L., Yang, X., Qiu, X., Qiao, Z., Song, X., Zhao, E., Zhou, J., Zhang, W., Mehmood, A., et al. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645418 · Cited by 40
“Additionally, the Framingham Heart Study has identified that high blood pressure and high cholesterol levels were independent key risk factors of heart diseases (Andersson et al., 2019).”
BackgroundPolygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes
Lu, T., Forgetta, V., Yu, O. H. Y., Mokry, L. E., Gregory, M., Thanassoulis, G., Greenwood, C. M. T., & Richards, J. B. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0988-9 · Cited by 47
Left Ventricular Diastolic Dysfunction in Type 2 Diabetes—Progress and Perspectives
Grigorescu, E.-D., Lăcătușu, C.-M., Floria, M., Mihai, B. M., Crețu, I., & Șorodoc, L. (2019) · Diagnostics · doi:10.3390/diagnostics9030121 · Cited by 43
Hsu, S.-H., Syu, D.-K., Chen, Y., Liu, C., Sun, C., & Chen, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137804 · Cited by 39
Addressing Comorbidities in Heart Failure
Bavishi, A. A., & Patel, R. B. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.005 · Cited by 50
Carotid ultrasound investigation as a prognostic tool for patients with diabetes mellitus
Hoke, M., Schillinger, M., Minar, E., Goliasch, G., Binder, C. J., & Mayer, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0895-0 · Cited by 35
Cho, M. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0245 · Cited by 38
Targeting Small GTPases and Their Prenylation in Diabetes Mellitus
Gendaszewska-Darmach, E., Garstka, M. A., & Błażewska, K. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00410 · Cited by 35
Heikkala, E., Mikkola, I., Jokelainen, J. J., Timonen, M., & Hagnäs, M. P. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06989-x · Cited by 40
Shaikh, K. A., Kinninger, A., Cherukuri, L., Birudaraju, D., Nakanishi, R., Almeida, S. O., Jayawardena, E., Shekar, C., Flores, F. R., Hamal, S. A., et al. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8371 · Cited by 36
How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sánchez-Fructuoso, A. I., de la Nieta, M. D. S., Agraz, I., & Soler, M. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112505 · Cited by 37
Use of Preventive Aspirin Among Older US Adults With and Without Diabetes
Liu, E. Y., Al‐Sofiani, M. E., Yeh, H., Echouffo-Tcheugui, J. B., Joseph, J. J., & Kalyani, R. R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.12210 · Cited by 35
Gyldenkerne, C., Knudsen, J. S., Olesen, K. K. W., Sørensen, H. T., Bøtker, H. E., Thomsen, R. W., & Mæng, M. (2021) · Diabetes Care · doi:10.2337/dc21-0383 · Cited by 36
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it
Jenkins, A. J., Januszewski, A. S., & O'Neal, D. N. (2019) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000169 · Cited by 36
North, E. J., & Newman, J. D. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000673 · Cited by 35
Viñals, C., Conget, I., Pané, A., Boswell, L., Perea, V., Blanco, J., Ruiz, S., Giménez, M., Vinagre, I., Esmatjes, E., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3320 · Cited by 35
Lim, L., Lau, E. S. H., Fung, E., Lee, H. M., Ronald, C. W., Tam, C. H. T., Wong, W. K. K., Ng, A. C. W., Chow, E., Luk, A. O. Y., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3253 · Cited by 45
Li, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Zhao, J., & Guo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069992 · Cited by 40
Bonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 36
Singh, L. G., Levitt, D. L., Satyarengga, M., Pinault, L. F., Zhan, M., Sorkin, J. D., Fink, J. C., Umpierrez, G. E., & Spanakis, E. K. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819889640 · Cited by 36
Nørgaard, C. H., Starkopf, L., Gerds, T. A., Vestergaard, P., Bonde, A. N., Fosbøl, E. L., Køber, L., Wong, N. D., Torp-Pedersen, C. T., & Lee, C. J.-Y. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab053 · Cited by 32
Rigato, M., Fadini, G. P., & Avogaro, A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15193 · Cited by 38
Alfian, S. D., Annisa, N., Fajriansyah, F., Perwitasari, D. A., Abdulah, R., Hak, E., & Denig, P. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05809-y · Cited by 34
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Park, C. S., Han, K., Choi, E., Kim, D. H., Lee, H., Lee, S., & Oh, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-84307-5 · Cited by 31
Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 42
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S103-S123
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4213222556
- Semantic Scholar
- b0a37d21ada65be89484f4b750bf45f281a7f7c5
- Cited by
- 471
- References
- 172
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 20 · 2023: 35 · 2022: 65 · 2021: 84 · 2020: 134 · 2019: 109
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care, treatment goals, level of evidence
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Risk Management, Societies, Medical, United States, Practice Guidelines as Topic, Diabetic Cardiomyopathies, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.